Cephalon Inc has won U.S. approval to sell its chemotherapy drug Treanda for treatment of patients with a type of non-Hodgkin's lymphoma.

 

The drug was previously approved in March by the U.S. Food and Drug Administration as a treatment for chronic lymphocytic leukemia, the most common form of leukemia in the United States. The latest approval applies to Treanda for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed despite treatment with Rituxan, or a regimen containing Rituxan, known generically as rituximab.

An estimated 30,000 people in the United States will be diagnosed this year with indolent NHL, a slow-growing cancer of the lymphatic system, according to the National Cancer Institute. Cephalon said a pivotal trial of Treanda showed that it delays progression of the disease for more than nine months.